Pathogen-free rats were rendered neutropenic, given oral feedings of Pseudomonas aeruginosa 12.4.4, then monitored for fever. At the onset of fever, rats were given intravenous treatment with either anti-endotoxin monoclonal antibody (MAb) E5 or control MAb B55. Survival was significantly greater in E5- than in B55-treated animals (P < .01). Serum levels of both lipopolysaccharide and tumor necrosis factor-alpha were significantly reduced in E5- versus B55-treated rats 24 h after treatment (P < .01 and < .05, respectively). Rats were also treated with E5 or B55 in combination with a suboptimal dose of ciprofloxacin at fever onset and again 24 h later. Survival was significantly greater in ciprofloxacin-treated animals given E5 than in animals given B55 (P < .005). Posttreatment endotoxin levels were decreased in animals receiving E5 in combination with ciprofloxacin (P < .001) compared with B55-treated animals. These results indicate that therapy with anti-endotoxin MAb E5 alone or in combination with antimicrobial therapy improves survival in this bacteremic infection model of Pseudomonas sepsis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/infdis/167.1.126 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock.
Cochrane Database Syst Rev
September 2013
Department of Clinical Epidemiology and Section of Infectious Diseases, Department of Medicine, Philippine General Hospital, University of the Philippines, Manila, Philippines, 1000.
Background: Mortality from sepsis and septic shock remains high. Results of trials on intravenous immunoglobulins (IVIG) as adjunctive therapy for sepsis have been conflicting. This is an update of a Cochrane review that was originally published in 1999 and updated in 2002 and 2010.
View Article and Find Full Text PDFThere were examined 34 children, in whom systemic inflammatory answer syndrome (SIAS) was diagnosed. In 16 children pathogenetically substantiated immunocorrection, using donor's plasma, enhanced by antibodies (AB) to endotoxin (ET), was conducted; in 18 children--the conventional complex therapy. While presence of gram-negative infection in children, suffering SIAS, the activation o the inborn nonspeciphic factors (LBP, sCD14) and speciphic low-affinic AB (anti-ET-IgM, anti-ET-IgA) the antiendotoxin immunity in combination with selective immunodeficiency of anti-ET-IgG were revealed.
View Article and Find Full Text PDF[Pharmacotherapy of sepsis].
G Ital Nefrol
July 2007
U.O.C. Nefrologia e Dialisi, Dipartimento Scienze Cliniche, Azienda Policlinico Umberto I, Università "La Sapienza", Roma.
Despite an increasingly understanding of the pathogenetic mechanisms of sepsis, its mortality remains extremely high, caused mainly by hemodynamic impairment-related alterations frequently present in severe sepsis. Currently, treatment of sepsis is based on hemodynamic support, antibiotic therapy, surgical excision of infectious foci and immunomodulatory therapy. In fact, a massive host inflammatory infection response has recently emerged to substantially contribute to the development of septic shock and multiple organ dysfunction.
View Article and Find Full Text PDFAnti-endotoxin monoclonal antibodies are protective against hepatic ischemia/reperfusion injury in steatotic mice.
Am J Transplant
October 2004
Department of Surgery, Division of Transplant, Medical University of South Carolina (MUSC), Charleston, SC, USA.
Steatotic mice are particularly susceptible to hepatic ischemia/reperfusion injury compared with their lean littermates. We have previously demonstrated that livers of mice having a spontaneous mutation in the leptin gene (ob/ob), resulting in global obesity and liver steatosis, are ATP depleted, are endotoxin sensitive, and do not survive (I/R) injury. We hypothesize that administration of an anti-LPS monoclonal antibody (mAb) prior to initiation of I/R would be protective from that insult.
View Article and Find Full Text PDF[The application of molecular biology to anti-endotoxin therapies].
Nihon Geka Gakkai Zasshi
July 2003
First Department of Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan.
Toll-like receptors (TLRs), recently identified on macrophages and dendritic cells in mammals, recognize a specific pattern of pathogen components, including endotoxins(lipopolysaccharide). Pathogen recognition by TLRs activates the innate immune system through the signaling pathway and provokes inflammatory responses, such as inducing the production of cytokines. Therefore the specific inhibition of the signaling pathway and the administration of excess inflammatory responses have useful potential in the management of sepsis syndrome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!